Risk of Insulin Resistance and Metabolic Syndrome in Women with Hyperandrogenemia: A Comparison between PCOS Phenotypes and Beyond
Authors:
- Valentin BorzanVBValentin Borzan
- Elisabeth LerchbaumELElisabeth Lerchbaum
- Cornelia MissbrennerCMCornelia Missbrenner
- Annemieke C. HeijboerAHAnnemieke C. Heijboer
- Michaela GoschnikMGMichaela Goschnik
- Christian TrummerCTChristian Trummer
- Verena Theiler-SchwetzVTVerena Theiler-Schwetz
- Christoph HaudumCHChristoph Haudum
- Roswitha GumpoldRGRoswitha Gumpold
- Natascha SchweighoferNSNatascha Schweighofer
- Barbara Obermayer-PietschBarbara Obermayer-Pietsch
Open Access
- 18 February 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (4) , 829
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in premenopausal women, with a wide spectrum of possible phenotypes, symptoms and sequelae according to the current clinical definition. However, there are women who do not fulfill at least two out of the three commonly used “Rotterdam criteria” and their risk of developing type 2 diabetes or obesity later in life is not defined. Therefore, we addressed this important gap by conducting a retrospective analysis based on 750 women with and without PCOS. We compared four different PCOS phenotypes according to the Rotterdam criteria with women who exhibit only one Rotterdam criterion and with healthy controls. Hormone and metabolic differences were assessed by analysis of variance (ANOVA) as well as logistic regression analysis. We found that hyperandrogenic women have per se a higher risk of developing insulin resistance compared to phenotypes without hyperandrogenism and healthy controls. In addition, hyperandrogenemia is associated with developing insulin resistance also in women with no other Rotterdam criterion. Our study encourages further diagnostic and therapeutic approaches for PCOS phenotypes in order to account for varying risks of developing metabolic diseases. Finally, women with hyperandrogenism as the only symptom should also be screened for insulin resistance to avoid later metabolic risks.Keywords
Funding Information
- Austrian Science Fund (KLI 274)
- Österreichische Forschungsförderungsgesellschaft (Comet K1)
This publication has 41 references indexed in Scilit:
- Epidemiology, diagnosis, and management of polycystic ovary syndromeClinical Epidemiology, 2013
- Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening methodHuman Reproduction, 2013
- Hypertriglyceridemic waist is associated with impaired glucose tolerance in polycystic ovary syndromeNutrition, Metabolism and Cardiovascular Diseases, 2012
- Relative Contributions of Oligomenorrhea and Hyperandrogenemia to the Risk of Metabolic Syndrome in Midlife WomenThe Journal of Clinical Endocrinology & Metabolism, 2012
- Inflammation in Polycystic Ovary Syndrome: Underpinning of insulin resistance and ovarian dysfunctionSteroids, 2012
- Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop GroupFertility and Sterility, 2012
- Fatty liver index in polycystic ovary syndromeEuropean Journal of Endocrinology, 2011
- Pathophysiology and types of dyslipidemia in PCOSTrends in Endocrinology & Metabolism, 2007
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005
- Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperatureThe Journal of Steroid Biochemistry and Molecular Biology, 1982